Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global Inactivated Vaccine for Swine Mycoplasma Pneumonia market size was valued at USD 351.9 million in 2022 and is forecast to a readjusted size of USD 568.1 million by 2029 with a CAGR of 7.1% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Inactivated vaccines for Swine Mycoplasma pneumonia are also available. They are made by using inactivated or killed strains of the bacteria to stimulate an immune response in pigs without causing disease.
This report is a detailed and comprehensive analysis for global Inactivated Vaccine for Swine Mycoplasma Pneumonia market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Inactivated Vaccine for Swine Mycoplasma Pneumonia market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Inactivated Vaccine for Swine Mycoplasma Pneumonia market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Inactivated Vaccine for Swine Mycoplasma Pneumonia market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Inactivated Vaccine for Swine Mycoplasma Pneumonia market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Inactivated Vaccine for Swine Mycoplasma Pneumonia
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Inactivated Vaccine for Swine Mycoplasma Pneumonia market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Zoetis, Boehringer Ingelheim, Jinhe Biotechnology, Merck and HIPRA, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Inactivated Vaccine for Swine Mycoplasma Pneumonia market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Inactivated Vaccine for Swine Mycoplasma Pneumonia product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Inactivated Vaccine for Swine Mycoplasma Pneumonia, with price, sales, revenue and global market share of Inactivated Vaccine for Swine Mycoplasma Pneumonia from 2018 to 2023.
Chapter 3, the Inactivated Vaccine for Swine Mycoplasma Pneumonia competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Inactivated Vaccine for Swine Mycoplasma Pneumonia breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Inactivated Vaccine for Swine Mycoplasma Pneumonia market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Inactivated Vaccine for Swine Mycoplasma Pneumonia.
Chapter 14 and 15, to describe Inactivated Vaccine for Swine Mycoplasma Pneumonia sales channel, distributors, customers, research findings and conclusion.
Inactivated vaccines for Swine Mycoplasma pneumonia are also available. They are made by using inactivated or killed strains of the bacteria to stimulate an immune response in pigs without causing disease.
This report is a detailed and comprehensive analysis for global Inactivated Vaccine for Swine Mycoplasma Pneumonia market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Inactivated Vaccine for Swine Mycoplasma Pneumonia market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Inactivated Vaccine for Swine Mycoplasma Pneumonia market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Inactivated Vaccine for Swine Mycoplasma Pneumonia market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Inactivated Vaccine for Swine Mycoplasma Pneumonia market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Inactivated Vaccine for Swine Mycoplasma Pneumonia
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Inactivated Vaccine for Swine Mycoplasma Pneumonia market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Zoetis, Boehringer Ingelheim, Jinhe Biotechnology, Merck and HIPRA, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Inactivated Vaccine for Swine Mycoplasma Pneumonia market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Single Vaccine
- Dual Vaccine
- Piglets
- Adult Pigs
- Zoetis
- Boehringer Ingelheim
- Jinhe Biotechnology
- Merck
- HIPRA
- Ceva Sant? Animale
- Harbin Pharmaceutical Group
- Pulike Biotech
- Qilu Animal Health Products
- Wuhan Keqian Biology
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Inactivated Vaccine for Swine Mycoplasma Pneumonia product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Inactivated Vaccine for Swine Mycoplasma Pneumonia, with price, sales, revenue and global market share of Inactivated Vaccine for Swine Mycoplasma Pneumonia from 2018 to 2023.
Chapter 3, the Inactivated Vaccine for Swine Mycoplasma Pneumonia competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Inactivated Vaccine for Swine Mycoplasma Pneumonia breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Inactivated Vaccine for Swine Mycoplasma Pneumonia market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Inactivated Vaccine for Swine Mycoplasma Pneumonia.
Chapter 14 and 15, to describe Inactivated Vaccine for Swine Mycoplasma Pneumonia sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Inactivated Vaccine for Swine Mycoplasma Pneumonia
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Single Vaccine
1.3.3 Dual Vaccine
1.4 Market Analysis by Application
1.4.1 Overview: Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Piglets
1.4.3 Adult Pigs
1.5 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size & Forecast
1.5.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity (2018-2029)
1.5.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 Zoetis
2.1.1 Zoetis Details
2.1.2 Zoetis Major Business
2.1.3 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
2.1.4 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Zoetis Recent Developments/Updates
2.2 Boehringer Ingelheim
2.2.1 Boehringer Ingelheim Details
2.2.2 Boehringer Ingelheim Major Business
2.2.3 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
2.2.4 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Boehringer Ingelheim Recent Developments/Updates
2.3 Jinhe Biotechnology
2.3.1 Jinhe Biotechnology Details
2.3.2 Jinhe Biotechnology Major Business
2.3.3 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
2.3.4 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Jinhe Biotechnology Recent Developments/Updates
2.4 Merck
2.4.1 Merck Details
2.4.2 Merck Major Business
2.4.3 Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
2.4.4 Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Merck Recent Developments/Updates
2.5 HIPRA
2.5.1 HIPRA Details
2.5.2 HIPRA Major Business
2.5.3 HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
2.5.4 HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 HIPRA Recent Developments/Updates
2.6 Ceva Sant? Animale
2.6.1 Ceva Sant? Animale Details
2.6.2 Ceva Sant? Animale Major Business
2.6.3 Ceva Sant? Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
2.6.4 Ceva Sant? Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Ceva Sant? Animale Recent Developments/Updates
2.7 Harbin Pharmaceutical Group
2.7.1 Harbin Pharmaceutical Group Details
2.7.2 Harbin Pharmaceutical Group Major Business
2.7.3 Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
2.7.4 Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Harbin Pharmaceutical Group Recent Developments/Updates
2.8 Pulike Biotech
2.8.1 Pulike Biotech Details
2.8.2 Pulike Biotech Major Business
2.8.3 Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
2.8.4 Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Pulike Biotech Recent Developments/Updates
2.9 Qilu Animal Health Products
2.9.1 Qilu Animal Health Products Details
2.9.2 Qilu Animal Health Products Major Business
2.9.3 Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
2.9.4 Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Qilu Animal Health Products Recent Developments/Updates
2.10 Wuhan Keqian Biology
2.10.1 Wuhan Keqian Biology Details
2.10.2 Wuhan Keqian Biology Major Business
2.10.3 Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
2.10.4 Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Wuhan Keqian Biology Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: INACTIVATED VACCINE FOR SWINE MYCOPLASMA PNEUMONIA BY MANUFACTURER
3.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Manufacturer (2018-2023)
3.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue by Manufacturer (2018-2023)
3.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Manufacturer Market Share in 2022
3.4.2 Top 6 Inactivated Vaccine for Swine Mycoplasma Pneumonia Manufacturer Market Share in 2022
3.5 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market: Overall Company Footprint Analysis
3.5.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market: Region Footprint
3.5.2 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market: Company Product Type Footprint
3.5.3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size by Region
4.1.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Region (2018-2029)
4.1.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Region (2018-2029)
4.1.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Region (2018-2029)
4.2 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value (2018-2029)
4.3 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value (2018-2029)
4.4 Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value (2018-2029)
4.5 South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value (2018-2029)
4.6 Middle East and Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2018-2029)
5.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Type (2018-2029)
5.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2018-2029)
6.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Application (2018-2029)
6.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2018-2029)
7.2 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2018-2029)
7.3 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size by Country
7.3.1 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Country (2018-2029)
7.3.2 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2018-2029)
8.2 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2018-2029)
8.3 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size by Country
8.3.1 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Country (2018-2029)
8.3.2 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size by Region
9.3.1 Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2018-2029)
10.2 South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2018-2029)
10.3 South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size by Country
10.3.1 South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Country (2018-2029)
10.3.2 South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size by Country
11.3.1 Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Drivers
12.2 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Restraints
12.3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Inactivated Vaccine for Swine Mycoplasma Pneumonia and Key Manufacturers
13.2 Manufacturing Costs Percentage of Inactivated Vaccine for Swine Mycoplasma Pneumonia
13.3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Process
13.4 Inactivated Vaccine for Swine Mycoplasma Pneumonia Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Inactivated Vaccine for Swine Mycoplasma Pneumonia Typical Distributors
14.3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope of Inactivated Vaccine for Swine Mycoplasma Pneumonia
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Single Vaccine
1.3.3 Dual Vaccine
1.4 Market Analysis by Application
1.4.1 Overview: Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Piglets
1.4.3 Adult Pigs
1.5 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size & Forecast
1.5.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity (2018-2029)
1.5.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 Zoetis
2.1.1 Zoetis Details
2.1.2 Zoetis Major Business
2.1.3 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
2.1.4 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Zoetis Recent Developments/Updates
2.2 Boehringer Ingelheim
2.2.1 Boehringer Ingelheim Details
2.2.2 Boehringer Ingelheim Major Business
2.2.3 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
2.2.4 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Boehringer Ingelheim Recent Developments/Updates
2.3 Jinhe Biotechnology
2.3.1 Jinhe Biotechnology Details
2.3.2 Jinhe Biotechnology Major Business
2.3.3 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
2.3.4 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Jinhe Biotechnology Recent Developments/Updates
2.4 Merck
2.4.1 Merck Details
2.4.2 Merck Major Business
2.4.3 Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
2.4.4 Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Merck Recent Developments/Updates
2.5 HIPRA
2.5.1 HIPRA Details
2.5.2 HIPRA Major Business
2.5.3 HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
2.5.4 HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 HIPRA Recent Developments/Updates
2.6 Ceva Sant? Animale
2.6.1 Ceva Sant? Animale Details
2.6.2 Ceva Sant? Animale Major Business
2.6.3 Ceva Sant? Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
2.6.4 Ceva Sant? Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Ceva Sant? Animale Recent Developments/Updates
2.7 Harbin Pharmaceutical Group
2.7.1 Harbin Pharmaceutical Group Details
2.7.2 Harbin Pharmaceutical Group Major Business
2.7.3 Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
2.7.4 Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Harbin Pharmaceutical Group Recent Developments/Updates
2.8 Pulike Biotech
2.8.1 Pulike Biotech Details
2.8.2 Pulike Biotech Major Business
2.8.3 Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
2.8.4 Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Pulike Biotech Recent Developments/Updates
2.9 Qilu Animal Health Products
2.9.1 Qilu Animal Health Products Details
2.9.2 Qilu Animal Health Products Major Business
2.9.3 Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
2.9.4 Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Qilu Animal Health Products Recent Developments/Updates
2.10 Wuhan Keqian Biology
2.10.1 Wuhan Keqian Biology Details
2.10.2 Wuhan Keqian Biology Major Business
2.10.3 Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
2.10.4 Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Wuhan Keqian Biology Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: INACTIVATED VACCINE FOR SWINE MYCOPLASMA PNEUMONIA BY MANUFACTURER
3.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Manufacturer (2018-2023)
3.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue by Manufacturer (2018-2023)
3.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Manufacturer Market Share in 2022
3.4.2 Top 6 Inactivated Vaccine for Swine Mycoplasma Pneumonia Manufacturer Market Share in 2022
3.5 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market: Overall Company Footprint Analysis
3.5.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market: Region Footprint
3.5.2 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market: Company Product Type Footprint
3.5.3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size by Region
4.1.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Region (2018-2029)
4.1.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Region (2018-2029)
4.1.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Region (2018-2029)
4.2 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value (2018-2029)
4.3 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value (2018-2029)
4.4 Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value (2018-2029)
4.5 South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value (2018-2029)
4.6 Middle East and Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2018-2029)
5.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Type (2018-2029)
5.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2018-2029)
6.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Application (2018-2029)
6.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2018-2029)
7.2 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2018-2029)
7.3 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size by Country
7.3.1 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Country (2018-2029)
7.3.2 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2018-2029)
8.2 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2018-2029)
8.3 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size by Country
8.3.1 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Country (2018-2029)
8.3.2 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size by Region
9.3.1 Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2018-2029)
10.2 South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2018-2029)
10.3 South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size by Country
10.3.1 South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Country (2018-2029)
10.3.2 South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size by Country
11.3.1 Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Drivers
12.2 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Restraints
12.3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Inactivated Vaccine for Swine Mycoplasma Pneumonia and Key Manufacturers
13.2 Manufacturing Costs Percentage of Inactivated Vaccine for Swine Mycoplasma Pneumonia
13.3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Process
13.4 Inactivated Vaccine for Swine Mycoplasma Pneumonia Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Inactivated Vaccine for Swine Mycoplasma Pneumonia Typical Distributors
14.3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Zoetis Basic Information, Manufacturing Base and Competitors
Table 4. Zoetis Major Business
Table 5. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
Table 6. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Zoetis Recent Developments/Updates
Table 8. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 9. Boehringer Ingelheim Major Business
Table 10. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
Table 11. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Boehringer Ingelheim Recent Developments/Updates
Table 13. Jinhe Biotechnology Basic Information, Manufacturing Base and Competitors
Table 14. Jinhe Biotechnology Major Business
Table 15. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
Table 16. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Jinhe Biotechnology Recent Developments/Updates
Table 18. Merck Basic Information, Manufacturing Base and Competitors
Table 19. Merck Major Business
Table 20. Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
Table 21. Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Merck Recent Developments/Updates
Table 23. HIPRA Basic Information, Manufacturing Base and Competitors
Table 24. HIPRA Major Business
Table 25. HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
Table 26. HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. HIPRA Recent Developments/Updates
Table 28. Ceva Sant? Animale Basic Information, Manufacturing Base and Competitors
Table 29. Ceva Sant? Animale Major Business
Table 30. Ceva Sant? Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
Table 31. Ceva Sant? Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Ceva Sant? Animale Recent Developments/Updates
Table 33. Harbin Pharmaceutical Group Basic Information, Manufacturing Base and Competitors
Table 34. Harbin Pharmaceutical Group Major Business
Table 35. Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
Table 36. Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Harbin Pharmaceutical Group Recent Developments/Updates
Table 38. Pulike Biotech Basic Information, Manufacturing Base and Competitors
Table 39. Pulike Biotech Major Business
Table 40. Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
Table 41. Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Pulike Biotech Recent Developments/Updates
Table 43. Qilu Animal Health Products Basic Information, Manufacturing Base and Competitors
Table 44. Qilu Animal Health Products Major Business
Table 45. Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
Table 46. Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Qilu Animal Health Products Recent Developments/Updates
Table 48. Wuhan Keqian Biology Basic Information, Manufacturing Base and Competitors
Table 49. Wuhan Keqian Biology Major Business
Table 50. Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
Table 51. Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Wuhan Keqian Biology Recent Developments/Updates
Table 53. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 54. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue by Manufacturer (2018-2023) & (USD Million)
Table 55. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 56. Market Position of Manufacturers in Inactivated Vaccine for Swine Mycoplasma Pneumonia, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 57. Head Office and Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Site of Key Manufacturer
Table 58. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market: Company Product Type Footprint
Table 59. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market: Company Product Application Footprint
Table 60. Inactivated Vaccine for Swine Mycoplasma Pneumonia New Market Entrants and Barriers to Market Entry
Table 61. Inactivated Vaccine for Swine Mycoplasma Pneumonia Mergers, Acquisition, Agreements, and Collaborations
Table 62. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Region (2018-2023) & (K Units)
Table 63. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Region (2024-2029) & (K Units)
Table 64. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Region (2018-2023) & (USD Million)
Table 65. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Region (2024-2029) & (USD Million)
Table 66. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Region (2018-2023) & (US$/Unit)
Table 67. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Region (2024-2029) & (US$/Unit)
Table 68. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2018-2023) & (K Units)
Table 69. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2024-2029) & (K Units)
Table 70. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Type (2018-2023) & (USD Million)
Table 71. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Type (2024-2029) & (USD Million)
Table 72. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Type (2018-2023) & (US$/Unit)
Table 73. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Type (2024-2029) & (US$/Unit)
Table 74. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2018-2023) & (K Units)
Table 75. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2024-2029) & (K Units)
Table 76. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Application (2018-2023) & (USD Million)
Table 77. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Application (2024-2029) & (USD Million)
Table 78. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Application (2018-2023) & (US$/Unit)
Table 79. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Application (2024-2029) & (US$/Unit)
Table 80. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2018-2023) & (K Units)
Table 81. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2024-2029) & (K Units)
Table 82. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2018-2023) & (K Units)
Table 83. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2024-2029) & (K Units)
Table 84. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Country (2018-2023) & (K Units)
Table 85. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Country (2024-2029) & (K Units)
Table 86. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Country (2018-2023) & (USD Million)
Table 87. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Country (2024-2029) & (USD Million)
Table 88. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2018-2023) & (K Units)
Table 89. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2024-2029) & (K Units)
Table 90. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2018-2023) & (K Units)
Table 91. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2024-2029) & (K Units)
Table 92. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Country (2018-2023) & (K Units)
Table 93. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Country (2024-2029) & (K Units)
Table 94. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Country (2018-2023) & (USD Million)
Table 95. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Country (2024-2029) & (USD Million)
Table 96. Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2018-2023) & (K Units)
Table 97. Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2024-2029) & (K Units)
Table 98. Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2018-2023) & (K Units)
Table 99. Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2024-2029) & (K Units)
Table 100. Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Region (2018-2023) & (K Units)
Table 101. Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Region (2024-2029) & (K Units)
Table 102. Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Region (2018-2023) & (USD Million)
Table 103. Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Region (2024-2029) & (USD Million)
Table 104. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2018-2023) & (K Units)
Table 105. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2024-2029) & (K Units)
Table 106. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2018-2023) & (K Units)
Table 107. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2024-2029) & (K Units)
Table 108. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Country (2018-2023) & (K Units)
Table 109. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Country (2024-2029) & (K Units)
Table 110. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Country (2018-2023) & (USD Million)
Table 111. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Country (2024-2029) & (USD Million)
Table 112. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2018-2023) & (K Units)
Table 113. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2024-2029) & (K Units)
Table 114. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2018-2023) & (K Units)
Table 115. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2024-2029) & (K Units)
Table 116. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Region (2018-2023) & (K Units)
Table 117. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Region (2024-2029) & (K Units)
Table 118. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Region (2018-2023) & (USD Million)
Table 119. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Region (2024-2029) & (USD Million)
Table 120. Inactivated Vaccine for Swine Mycoplasma Pneumonia Raw Material
Table 121. Key Manufacturers of Inactivated Vaccine for Swine Mycoplasma Pneumonia Raw Materials
Table 122. Inactivated Vaccine for Swine Mycoplasma Pneumonia Typical Distributors
Table 123. Inactivated Vaccine for Swine Mycoplasma Pneumonia Typical Customers
Table 1. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Zoetis Basic Information, Manufacturing Base and Competitors
Table 4. Zoetis Major Business
Table 5. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
Table 6. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Zoetis Recent Developments/Updates
Table 8. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 9. Boehringer Ingelheim Major Business
Table 10. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
Table 11. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Boehringer Ingelheim Recent Developments/Updates
Table 13. Jinhe Biotechnology Basic Information, Manufacturing Base and Competitors
Table 14. Jinhe Biotechnology Major Business
Table 15. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
Table 16. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Jinhe Biotechnology Recent Developments/Updates
Table 18. Merck Basic Information, Manufacturing Base and Competitors
Table 19. Merck Major Business
Table 20. Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
Table 21. Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Merck Recent Developments/Updates
Table 23. HIPRA Basic Information, Manufacturing Base and Competitors
Table 24. HIPRA Major Business
Table 25. HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
Table 26. HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. HIPRA Recent Developments/Updates
Table 28. Ceva Sant? Animale Basic Information, Manufacturing Base and Competitors
Table 29. Ceva Sant? Animale Major Business
Table 30. Ceva Sant? Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
Table 31. Ceva Sant? Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Ceva Sant? Animale Recent Developments/Updates
Table 33. Harbin Pharmaceutical Group Basic Information, Manufacturing Base and Competitors
Table 34. Harbin Pharmaceutical Group Major Business
Table 35. Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
Table 36. Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Harbin Pharmaceutical Group Recent Developments/Updates
Table 38. Pulike Biotech Basic Information, Manufacturing Base and Competitors
Table 39. Pulike Biotech Major Business
Table 40. Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
Table 41. Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Pulike Biotech Recent Developments/Updates
Table 43. Qilu Animal Health Products Basic Information, Manufacturing Base and Competitors
Table 44. Qilu Animal Health Products Major Business
Table 45. Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
Table 46. Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Qilu Animal Health Products Recent Developments/Updates
Table 48. Wuhan Keqian Biology Basic Information, Manufacturing Base and Competitors
Table 49. Wuhan Keqian Biology Major Business
Table 50. Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product and Services
Table 51. Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Wuhan Keqian Biology Recent Developments/Updates
Table 53. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 54. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue by Manufacturer (2018-2023) & (USD Million)
Table 55. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 56. Market Position of Manufacturers in Inactivated Vaccine for Swine Mycoplasma Pneumonia, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 57. Head Office and Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Site of Key Manufacturer
Table 58. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market: Company Product Type Footprint
Table 59. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market: Company Product Application Footprint
Table 60. Inactivated Vaccine for Swine Mycoplasma Pneumonia New Market Entrants and Barriers to Market Entry
Table 61. Inactivated Vaccine for Swine Mycoplasma Pneumonia Mergers, Acquisition, Agreements, and Collaborations
Table 62. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Region (2018-2023) & (K Units)
Table 63. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Region (2024-2029) & (K Units)
Table 64. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Region (2018-2023) & (USD Million)
Table 65. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Region (2024-2029) & (USD Million)
Table 66. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Region (2018-2023) & (US$/Unit)
Table 67. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Region (2024-2029) & (US$/Unit)
Table 68. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2018-2023) & (K Units)
Table 69. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2024-2029) & (K Units)
Table 70. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Type (2018-2023) & (USD Million)
Table 71. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Type (2024-2029) & (USD Million)
Table 72. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Type (2018-2023) & (US$/Unit)
Table 73. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Type (2024-2029) & (US$/Unit)
Table 74. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2018-2023) & (K Units)
Table 75. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2024-2029) & (K Units)
Table 76. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Application (2018-2023) & (USD Million)
Table 77. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Application (2024-2029) & (USD Million)
Table 78. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Application (2018-2023) & (US$/Unit)
Table 79. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Application (2024-2029) & (US$/Unit)
Table 80. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2018-2023) & (K Units)
Table 81. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2024-2029) & (K Units)
Table 82. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2018-2023) & (K Units)
Table 83. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2024-2029) & (K Units)
Table 84. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Country (2018-2023) & (K Units)
Table 85. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Country (2024-2029) & (K Units)
Table 86. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Country (2018-2023) & (USD Million)
Table 87. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Country (2024-2029) & (USD Million)
Table 88. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2018-2023) & (K Units)
Table 89. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2024-2029) & (K Units)
Table 90. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2018-2023) & (K Units)
Table 91. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2024-2029) & (K Units)
Table 92. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Country (2018-2023) & (K Units)
Table 93. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Country (2024-2029) & (K Units)
Table 94. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Country (2018-2023) & (USD Million)
Table 95. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Country (2024-2029) & (USD Million)
Table 96. Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2018-2023) & (K Units)
Table 97. Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2024-2029) & (K Units)
Table 98. Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2018-2023) & (K Units)
Table 99. Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2024-2029) & (K Units)
Table 100. Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Region (2018-2023) & (K Units)
Table 101. Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Region (2024-2029) & (K Units)
Table 102. Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Region (2018-2023) & (USD Million)
Table 103. Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Region (2024-2029) & (USD Million)
Table 104. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2018-2023) & (K Units)
Table 105. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2024-2029) & (K Units)
Table 106. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2018-2023) & (K Units)
Table 107. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2024-2029) & (K Units)
Table 108. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Country (2018-2023) & (K Units)
Table 109. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Country (2024-2029) & (K Units)
Table 110. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Country (2018-2023) & (USD Million)
Table 111. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Country (2024-2029) & (USD Million)
Table 112. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2018-2023) & (K Units)
Table 113. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Type (2024-2029) & (K Units)
Table 114. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2018-2023) & (K Units)
Table 115. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Application (2024-2029) & (K Units)
Table 116. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Region (2018-2023) & (K Units)
Table 117. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity by Region (2024-2029) & (K Units)
Table 118. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Region (2018-2023) & (USD Million)
Table 119. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Region (2024-2029) & (USD Million)
Table 120. Inactivated Vaccine for Swine Mycoplasma Pneumonia Raw Material
Table 121. Key Manufacturers of Inactivated Vaccine for Swine Mycoplasma Pneumonia Raw Materials
Table 122. Inactivated Vaccine for Swine Mycoplasma Pneumonia Typical Distributors
Table 123. Inactivated Vaccine for Swine Mycoplasma Pneumonia Typical Customers
LIST OF FIGURES
Figure 1. Inactivated Vaccine for Swine Mycoplasma Pneumonia Picture
Figure 2. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value Market Share by Type in 2022
Figure 4. Single Vaccine Examples
Figure 5. Dual Vaccine Examples
Figure 6. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 7. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value Market Share by Application in 2022
Figure 8. Piglets Examples
Figure 9. Adult Pigs Examples
Figure 10. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 11. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 12. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity (2018-2029) & (K Units)
Figure 13. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price (2018-2029) & (US$/Unit)
Figure 14. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Manufacturer in 2022
Figure 15. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value Market Share by Manufacturer in 2022
Figure 16. Producer Shipments of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 17. Top 3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Manufacturer (Consumption Value) Market Share in 2022
Figure 18. Top 6 Inactivated Vaccine for Swine Mycoplasma Pneumonia Manufacturer (Consumption Value) Market Share in 2022
Figure 19. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Region (2018-2029)
Figure 20. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value Market Share by Region (2018-2029)
Figure 21. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value (2018-2029) & (USD Million)
Figure 22. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value (2018-2029) & (USD Million)
Figure 23. Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value (2018-2029) & (USD Million)
Figure 24. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value (2018-2029) & (USD Million)
Figure 25. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value (2018-2029) & (USD Million)
Figure 26. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Type (2018-2029)
Figure 27. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value Market Share by Type (2018-2029)
Figure 28. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Type (2018-2029) & (US$/Unit)
Figure 29. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Application (2018-2029)
Figure 30. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value Market Share by Application (2018-2029)
Figure 31. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Application (2018-2029) & (US$/Unit)
Figure 32. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Type (2018-2029)
Figure 33. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Application (2018-2029)
Figure 34. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Country (2018-2029)
Figure 35. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value Market Share by Country (2018-2029)
Figure 36. United States Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 37. Canada Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 38. Mexico Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Type (2018-2029)
Figure 40. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Application (2018-2029)
Figure 41. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Country (2018-2029)
Figure 42. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value Market Share by Country (2018-2029)
Figure 43. Germany Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 44. France Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. United Kingdom Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. Russia Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. Italy Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Type (2018-2029)
Figure 49. Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Application (2018-2029)
Figure 50. Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Region (2018-2029)
Figure 51. Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value Market Share by Region (2018-2029)
Figure 52. China Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 53. Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Korea Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. India Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Southeast Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Australia Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Type (2018-2029)
Figure 59. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Application (2018-2029)
Figure 60. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Country (2018-2029)
Figure 61. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value Market Share by Country (2018-2029)
Figure 62. Brazil Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 63. Argentina Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Type (2018-2029)
Figure 65. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Application (2018-2029)
Figure 66. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Region (2018-2029)
Figure 67. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value Market Share by Region (2018-2029)
Figure 68. Turkey Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 69. Egypt Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Saudi Arabia Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. South Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Drivers
Figure 73. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Restraints
Figure 74. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Trends
Figure 75. Porters Five Forces Analysis
Figure 76. Manufacturing Cost Structure Analysis of Inactivated Vaccine for Swine Mycoplasma Pneumonia in 2022
Figure 77. Manufacturing Process Analysis of Inactivated Vaccine for Swine Mycoplasma Pneumonia
Figure 78. Inactivated Vaccine for Swine Mycoplasma Pneumonia Industrial Chain
Figure 79. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 80. Direct Channel Pros & Cons
Figure 81. Indirect Channel Pros & Cons
Figure 82. Methodology
Figure 83. Research Process and Data Source
Figure 1. Inactivated Vaccine for Swine Mycoplasma Pneumonia Picture
Figure 2. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value Market Share by Type in 2022
Figure 4. Single Vaccine Examples
Figure 5. Dual Vaccine Examples
Figure 6. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 7. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value Market Share by Application in 2022
Figure 8. Piglets Examples
Figure 9. Adult Pigs Examples
Figure 10. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 11. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 12. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity (2018-2029) & (K Units)
Figure 13. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price (2018-2029) & (US$/Unit)
Figure 14. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Manufacturer in 2022
Figure 15. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value Market Share by Manufacturer in 2022
Figure 16. Producer Shipments of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 17. Top 3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Manufacturer (Consumption Value) Market Share in 2022
Figure 18. Top 6 Inactivated Vaccine for Swine Mycoplasma Pneumonia Manufacturer (Consumption Value) Market Share in 2022
Figure 19. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Region (2018-2029)
Figure 20. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value Market Share by Region (2018-2029)
Figure 21. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value (2018-2029) & (USD Million)
Figure 22. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value (2018-2029) & (USD Million)
Figure 23. Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value (2018-2029) & (USD Million)
Figure 24. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value (2018-2029) & (USD Million)
Figure 25. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value (2018-2029) & (USD Million)
Figure 26. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Type (2018-2029)
Figure 27. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value Market Share by Type (2018-2029)
Figure 28. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Type (2018-2029) & (US$/Unit)
Figure 29. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Application (2018-2029)
Figure 30. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value Market Share by Application (2018-2029)
Figure 31. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Application (2018-2029) & (US$/Unit)
Figure 32. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Type (2018-2029)
Figure 33. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Application (2018-2029)
Figure 34. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Country (2018-2029)
Figure 35. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value Market Share by Country (2018-2029)
Figure 36. United States Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 37. Canada Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 38. Mexico Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Type (2018-2029)
Figure 40. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Application (2018-2029)
Figure 41. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Country (2018-2029)
Figure 42. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value Market Share by Country (2018-2029)
Figure 43. Germany Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 44. France Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. United Kingdom Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. Russia Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. Italy Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Type (2018-2029)
Figure 49. Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Application (2018-2029)
Figure 50. Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Region (2018-2029)
Figure 51. Asia-Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value Market Share by Region (2018-2029)
Figure 52. China Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 53. Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Korea Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. India Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Southeast Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Australia Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Type (2018-2029)
Figure 59. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Application (2018-2029)
Figure 60. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Country (2018-2029)
Figure 61. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value Market Share by Country (2018-2029)
Figure 62. Brazil Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 63. Argentina Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Type (2018-2029)
Figure 65. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Application (2018-2029)
Figure 66. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Quantity Market Share by Region (2018-2029)
Figure 67. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value Market Share by Region (2018-2029)
Figure 68. Turkey Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 69. Egypt Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Saudi Arabia Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. South Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Drivers
Figure 73. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Restraints
Figure 74. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Trends
Figure 75. Porters Five Forces Analysis
Figure 76. Manufacturing Cost Structure Analysis of Inactivated Vaccine for Swine Mycoplasma Pneumonia in 2022
Figure 77. Manufacturing Process Analysis of Inactivated Vaccine for Swine Mycoplasma Pneumonia
Figure 78. Inactivated Vaccine for Swine Mycoplasma Pneumonia Industrial Chain
Figure 79. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 80. Direct Channel Pros & Cons
Figure 81. Indirect Channel Pros & Cons
Figure 82. Methodology
Figure 83. Research Process and Data Source
